Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo
Metrics: PDF 738 views | HTML 1463 views | ?
Lei Zhou1,2,3, Zhixin Wang2,4, Xinsen Xu2, Yong Wan2, Kai Qu2, Haining Fan4, Qiangpu Chen1, Xuejun Sun3, Chang Liu2
1Department of Hepatobiliary Surgery, The Affiliated Hospital of Binzhou Medical University, Binzhou, China
2Department of Hepatobiliary Surgery, The First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China
3Department of General Surgery, The First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China
4Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qinghai University, Xining, China
Qiangpu Chen, e-mail: firstname.lastname@example.org
Xuejun Sun, e-mail: email@example.com
Chang Liu, e-mail: firstname.lastname@example.org
Keywords: Nek7, hepatocellular carcinoma, cell proliferation, cyclin B1, prognosis
Received: October 20, 2015 Accepted: January 24, 2016 Published: February 23, 2016
NIMA-related kinase-7 (Nek7) is a serine/threonine kinase involved in cell-cycle progression via mitotic spindle formation and cytokinesis. In this study, we investigated whether Nek7 involves in hepatocellular carcinoma (HCC). Interestingly, we found that Nek7 was significantly overexpressed in HCC than in liver tissues. In HCC patients, high Nek7 expression was significantly correlated with tumor numbers, tumor diameter, adjacent organs invasion, tumor grade and TNM stage. Furthermore, Nek7 expression pattern showed close relationship with that of Ki-67, a well-stablished cell proliferation marker. More importantly, patients with higher expression levels of Nek7 had significantly lower 5-years survival rate. Likewise, Nek7 expression was significantly higher in HCC cell lines than normal hepatic cell line. By Nek7 silencing using lentivirus-mediated Nek7 interference approach, the growth of HCC cell lines was inhibited and the tumor growth in xenograft mouse model was also suppressed. Mechanistic studies showed that silencing of Nek7 resulted in decreasing cyclinB1 level both in vitro and in vivo. In conclusion, this study highlights for the first time the possible role of Nek7 in HCC progression. Nek7 would be a useful biomarker that early predicts HCC patients at higher risk of poor prognosis. Also, Nek7 could be a novel HCC therapeutic target.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.